February 08, 2024

Amneal Announces Complete Response Resubmission for IPX203 New Drug Application

December 21, 2023

Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

December 15, 2023

Amneal Announces Move to Nasdaq

December 07, 2023

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

December 01, 2023

Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules

November 07, 2023

Amneal Reports Third Quarter 2023 Financial Results

November 03, 2023

Amneal to Participate at Upcoming Investor Conferences

October 12, 2023

Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio

October 05, 2023

Amneal to Report Third Quarter 2023 Results on November 7, 2023

September 06, 2023

Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection

September 06, 2023

 Amneal Receives First Product Approval in China

September 06, 2023

 Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate

August 29, 2023

Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India

August 25, 2023

Amneal to Participate at the 2023 Wells Fargo Healthcare Conference

August 24, 2023

JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease

August 04, 2023

Amneal Reports Second Quarter 2023 Financial Results

July 26, 2023

Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

July 06, 2023

Amneal to Report Second Quarter 2023 Results on August 4, 2023

July 03, 2023

Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

July 03, 2023

Amneal Receives U.S. FDA Complete Response Letter for IPX203

June 15, 2023

Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals

June 14, 2023

Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable

May 24, 2023

Amneal to Participate at the 2023 Jefferies Healthcare Conference

May 16, 2023

Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States

May 05, 2023

Amneal Reports First Quarter 2023 Financial Results

April 17, 2023

Amneal to Participate at the 22nd Annual Needham Virtual Healthcare Conference

April 17, 2023

Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance

April 12, 2023

Amneal to Report First Quarter 2023 Results on May 5, 2023

March 02, 2023

Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

March 02, 2023

Amneal Reports Fourth Quarter and Full Year 2022 Financial Results

January 31, 2023

Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023

January 04, 2023

Amneal Announces Strategic European Partnership with Orion Corporation

December 20, 2022

Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

November 23, 2022

Amneal to Participate at Upcoming Investor Conferences

November 22, 2022

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

November 11, 2022

Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

November 04, 2022

Amneal Reports Third Quarter 2022 Financial Results

November 02, 2022

Amneal Receives FDA Approval for Leuprolide Acetate Injection

October 31, 2022

Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and Regulatory

October 06, 2022

Amneal to Report Third Quarter 2022 Results on November 4, 2022

October 03, 2022

Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States

September 06, 2022

Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty

August 31, 2022

Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

August 22, 2022

Amneal supports Congress’ efforts to ensure essential medicines are Made in America

August 11, 2022

Amneal launches 4 new Generic products, including Vasopressin single-dose

August 05, 2022

Amneal Reports Second Quarter 2022 Financial Results

August 03, 2022

Amneal Appoints Deborah M. Autor to Board of Directors

July 08, 2022

Amneal to Report Second Quarter 2022 Results on August 5, 2022

June 01, 2022

Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders

May 27, 2022

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)